At a Glance
Biotech / Therapeutics
11-50
Overview
Appia Bio is a preclinical-stage biotechnology company established in 2020, dedicated to developing off-the-shelf cell therapies to treat cancer. Utilizing a proprietary platform, Appia Bio generates a diverse range of allogeneic NKT and T cell types, engineered to tackle the specific challenges found within tumor microenvironments. The company aims to accelerate the discovery and development of these therapies across various cancer indications while ensuring that treatments are scalable and accessible to patients. Guided by a team with extensive expertise in research and development, Appia Bio emphasizes collaboration and innovation in its scientific endeavors, supported by strong partnerships with leading academic institutions. Their commitment to addressing significant unmet medical needs in oncology drives their mission and culture.
Actions